ImmunityBio (NASDAQ: IBRX) completed enrollment in its pivotal QUILT 2.005 trial ahead of schedule with 366 patients, showing 85% complete response rate with Anktiva plus BCG versus 57% with BCG alone at six months. The company reported a 750% unit sales increase for Anktiva and revenue surging to $38.29 million, exceeding consensus estimates. An FDA biologics license application is anticipated by Q4 2026. Shares rose 3.97% in premarket trading.

ImmunityBio announced a distribution partnership with Accord Healthcare to commercialize its bladder cancer drug Anktiva across 30 European countries using an 85-person sales force. The company also established an Irish subsidiary to support its European distribution strategy. Despite the positive business development, IBRX shares declined 2.75% in premarket trading, tracking broader market weakness.

ImmunityBio stock surged 41.36% on Feb. 18, 2026, after the European Commission granted conditional marketing authorization for its Anktiva immunotherapy to treat bladder cancer. The approval expands access to over 30 new countries and positions the drug for accelerated sales growth. Despite the positive news, the stock remains volatile and heavily dependent on Anktiva's continued success.

Several biotech companies are advancing novel cancer treatments through clinical development. Oncolytics Biotech received FDA Fast Track Designation for pelareorep in KRAS-mutant colorectal cancer, showing doubled survival benefits. Novocure gained FDA approval for Optune Pax for pancreatic cancer. Perspective Therapeutics presented positive interim data for its radiopharmaceutical VMT-α-NET. ImmunityBio launched a Phase 2 trial for its CAR-NK cell therapy combined with IL-15 superagonist. Nuvation Bio expanded its Phase 3 trial for safusidenib in IDH1-mutant glioma.

The article identifies the top 10 most heavily shorted stocks as of February 13, 2026, led by Choice Hotels International (57.32% short interest), Lucid Group (51.78%), and Avis Budget Group (48.72%). It explains that stocks become heavily shorted when investors believe they are overvalued and face significant risks, while retail traders view high short interest as potential short squeeze opportunities. The article cautions that while monitoring short interest can help identify potential squeezes, timing such trades is extremely challenging and investors should conduct thorough due diligence given the underlying business risks.

Pomerantz Law Firm has filed class action lawsuits against Bath & Body Works for alleged securities fraud following significant financial misses and guidance cuts. In Q2 2025, the company reported a 55.8% decline in EPS and missed guidance, causing a 6.9% stock drop. Q3 results were worse, with a 1% revenue decline versus expected growth and a 24.8% stock plunge after slashing full-year guidance to negative growth and cutting EPS expectations to at least $2.83. The firm is also investigating claims against BellRing Brands and ImmunityBio.

The article identifies 10 heavily shorted stocks that could be potential short squeeze targets as of February 2, 2026. It explains how short squeezes work as a volatile feedback loop where rising stock prices force short sellers to cover positions, creating explosive gains. The most shorted stocks include Choice Hotels (56.33%), Lucid Group (54.45%), and Avis Budget Group (52.38%), among others. The article cautions that while monitoring short interest can help identify squeeze opportunities, timing such trades is extremely challenging and investors should conduct due diligence as volatility often reflects underlying business risks.

January 2026 saw extreme stock movements driven by earnings surprises and sector disruptions. Top gainers included SanDisk (up 150%), Cameco (up 37%), and Lockheed Martin (up 30%), while software stocks suffered historic declines with Braze, HubSpot, Rubrik, Guidewire, and GoDaddy all posting worst months on record. Microsoft's weak Azure guidance triggered a broader software sector selloff, with the IGV ETF down 14% for the month.

ImmunityBio surged 17.39% on January 20, 2026, following FDA end-of-phase discussions that outlined a resubmission path for its ANKTIVA therapy in BCG-unresponsive papillary bladder cancer. The stock has more than doubled in five days, driven by triple-digit revenue growth and expanding indications for its primary therapy, though investors should expect continued volatility.

The article identifies the top 10 most heavily shorted stocks in the market as of January 16, 2026, with short interest ranging from 36-56%. These stocks are highlighted as potential candidates for short squeezes, where unexpected price increases force short sellers to cover positions, creating rapid gains. The list includes Choice Hotels International (56.33% short interest), Lucid Group (54.45%), and Avis Budget Group (52.38%), among others. The article cautions that while short squeezes can yield outsized returns, timing is difficult and underlying business risks often justify the high short interest.

U.S. stock futures rose on Friday following Thursday's positive close, with chip stocks leading gains after Taiwan Semiconductor Manufacturing Co. posted record quarterly results. Financial stocks also rallied with Goldman Sachs and Morgan Stanley posting strong earnings. Key movers included Chevron expanding gas production, Paysafe forming a strategic partnership, J.B. Hunt reporting mixed results, ImmunityBio surging on strong product revenue, and QXO declining after announcing a stock offering.

ImmunityBio (IBRX) shares surged 28% on January 15, 2026, following announcement of exceptional preliminary 2025 financial results. The company reported approximately $113 million in net product revenue, a 700% year-over-year increase driven by accelerating adoption of its flagship immunotherapy drug ANKTIVA for bladder cancer. Q4 2025 revenue reached $38.3 million with 54% quarter-over-quarter unit volume growth. Analyst consensus remains bullish with an average 12-month price target of $10.40, representing over 200% upside potential.